Physician profile
Sean Li
NPI 1386623130
$1,237,826.40
in general payments reported to CMS, 2019-2025
63 companies · $163K in 2025
The $163K reported for 2025 was more than what 99% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $237K · 2020: $131K · 2021: $157K · 2022: $215K · 2023: $204K · 2024: $131K · 2025: $163K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $282K · Honoraria: $68K · Travel and Lodging: $57K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $33K · Food and Beverage: $31K · Education: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $281,775.99 |
| Honoraria | $67,612.00 |
| Travel and Lodging | $57,198.10 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $33,254.00 |
| Food and Beverage | $31,463.03 |
| Education | $23,123.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,647.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $213,379.56 | 2019-2024 | Senza, Omnia |
| Spr Therapeutics, INC | $143,988.61 | 2019-2025 | Sprint Pns System |
| Saluda Medical Americas, INC. | $141,632.05 | 2019-2025 | Evoke Scs, Evoke |
| Boston Scientific Corporation | $138,881.85 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Avanos Medical | $116,373.97 | 2019-2025 | Coolief* Cooled Radiofrequency, Cooled Rfa, Coolief |
| Vertiflex, INC. | $66,765.57 | 2019 | |
| Neuroone Medical Technologies Corporation | $52,199.06 | 2023-2025 | |
| Si-Bone, INC. | $50,434.69 | 2019-2025 | |
| Painteq LLC | $50,220.25 | 2021-2025 | Painteq |
| Nalu Medical, INC. | $47,186.71 | 2020-2025 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $41,147.18 | 2019-2024 | Mild Device Kit |
| Abbott Laboratories | $39,482.30 | 2019-2025 | Proclaim, Eterna |
| Biotronik Nro, INC. | $39,278.97 | 2023-2025 | Prospera, Biotronik |
| Averitas Pharma INC. | $18,643.11 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $15,254.24 | 2020-2025 | Qutenza |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $14,662.80 | 2024-2025 | Mild Device Kit, Omnicurve, Optablate |
| Biotronik INC. | $11,844.84 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $8,900.38 | 2019-2024 | Ztlido |
| Medtronic, INC. | $5,522.75 | 2021-2025 | Intellis Adaptivestim, Rialto Si Fusion System, Inceptiv |
| Ferring Pharmaceuticals INC. | $5,433.36 | 2020-2024 | |
| Relievant Medsystems, INC. | $2,692.47 | 2021-2022 | |
| Lilly USA, LLC | $2,250.00 | 2019 | |
| Mml US, INC. | $2,147.98 | 2021-2024 | Reactiv8 |
| Spinal Simplicity, LLC | $1,797.07 | 2022-2025 | Ha Minuteman G3-R |
| Medtronic USA, INC. | $1,683.87 | 2019-2020 | |
| Globus Medical, INC. | $747.25 | 2025 | Senza, Corridor |
| Collegium Pharmaceutical, INC. | $725.84 | 2019-2025 | Belbuca |
| Surgentec | $604.44 | 2025 | Ion |
| Tersera Therapeutics LLC | $566.92 | 2019-2025 | Prialt |
| Spinal Elements, INC. | $375.69 | 2024-2025 | |
| Alphatec Spine, INC | $357.27 | 2024 | Invictus Mis |
| Depuy Synthes Sales INC. | $323.97 | 2020-2025 | Orthovisc, Monovisc |
| Curonix LLC | $318.22 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nuvasive, INC. | $282.11 | 2019-2022 | |
| Horizon Therapeutics Plc | $270.00 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $227.34 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.88 | 2023-2025 | Relistor |
| Fidia Pharma USA INC. | $86.19 | 2019 | |
| Mdd US Operations, LLC | $82.30 | 2020 | |
| Almatica Pharma LLC | $69.74 | 2021 | |
| Pfizer INC. | $61.39 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $57.69 | 2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $52.67 | 2025 | |
| Flowonix Medical Incorporated | $50.25 | 2019 | |
| Valinor Pharma, LLC | $49.55 | 2024 | Movantik |
| Supernus Pharmaceuticals, INC. | $48.54 | 2019 | |
| Abbvie INC. | $47.29 | 2021-2022 | |
| Pacira Therapeutics, INC. | $46.82 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $44.12 | 2019-2023 | Iovera, Zilretta, Exparel |
| Teva Pharmaceuticals USA, INC. | $41.72 | 2019-2020 | |
| Uswm, LLC | $41.62 | 2021 | |
| Foundation Fusion Solutions, LLC | $36.13 | 2022-2025 | |
| Tris Pharma INC | $33.68 | 2022 | |
| Bioventus LLC | $32.10 | 2021-2024 | Durolane |
| Protega Pharmaceutials INC | $29.63 | 2023 | Roxybond |
| Zyla Life Sciences, INC. | $28.10 | 2020 | |
| Ibsa Pharma INC. | $27.65 | 2021-2024 | Tirosint, Licart |
| Assertio Therapeutics, INC. | $24.57 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $19.12 | 2025 | Kristalose |
| Vertical Pharmaceuticals, LLC | $14.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.79 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.62 | 2023 | Horizant |
| Astrazeneca Pharmaceuticals Lp | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,685.87 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.